Carboplatin: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>Robert Badgett No edit summary |
||
| Line 3: | Line 3: | ||
As compared to [[cisplatin]], carboplatin has equal ([[lung cancer]], [[ovarian cancer]]) or less ([[germ cell tumor]]s, [[bladder cancer]], [[head and neck cancer]]) efficacy but less [[drug toxicity]].<ref name="pmid9541678">{{cite journal| author=Lokich J, Anderson N| title=Carboplatin versus cisplatin in solid tumors: an analysis of the literature. | journal=Ann Oncol | year= 1998 | volume= 9 | issue= 1 | pages= 13-21 | pmid=9541678 | As compared to [[cisplatin]], carboplatin has equal ([[lung cancer]], [[ovarian cancer]]) or less ([[germ cell tumor]]s, [[bladder cancer]], [[head and neck cancer]]) efficacy but less [[drug toxicity]].<ref name="pmid9541678">{{cite journal| author=Lokich J, Anderson N| title=Carboplatin versus cisplatin in solid tumors: an analysis of the literature. | journal=Ann Oncol | year= 1998 | volume= 9 | issue= 1 | pages= 13-21 | pmid=9541678 | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=9541678 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=9541678 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> | ||
==Dosage== | |||
Carboplatin may be dosed by the Calvert formula:<ref name="pmid2681557">{{cite journal| author=Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE et al.| title=Carboplatin dosage: prospective evaluation of a simple formula based on renal function. | journal=J Clin Oncol | year= 1989 | volume= 7 | issue= 11 | pages= 1748-56 | pmid=2681557 | |||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=2681557 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> | |||
:<math>{{Dose\ (mg) =\ target\ AUC \times (GFR + 25)}}</math> | |||
==History== | ==History== | ||
Revision as of 15:06, 8 September 2009
In oncology, carboplatin is a antineoplastic agent that is an "organoplatinum compound that possesses antineoplastic activity."[1]
As compared to cisplatin, carboplatin has equal (lung cancer, ovarian cancer) or less (germ cell tumors, bladder cancer, head and neck cancer) efficacy but less drug toxicity.[2]
Dosage
Carboplatin may be dosed by the Calvert formula:[3]
History
In the United States, it was approved with a New Drug Application (NDA) by the FDA in 1989.[4] A generic version was approved with a Abbreviated New Drug Application (ANDA) in 2003.[5]
External links
The most up-to-date information about Carboplatin and other drugs can be found at the following sites.
- Carboplatin - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Carboplatin - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Carboplatin - Detailed information from DrugBank.
References
- ↑ Anonymous (2024), Carboplatin (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Lokich J, Anderson N (1998). "Carboplatin versus cisplatin in solid tumors: an analysis of the literature.". Ann Oncol 9 (1): 13-21. PMID 9541678.
- ↑ Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE et al. (1989). "Carboplatin dosage: prospective evaluation of a simple formula based on renal function.". J Clin Oncol 7 (11): 1748-56. PMID 2681557.
- ↑ Drugs@FDA. U S Food and Drug Administration
- ↑ Drugs@FDA. U S Food and Drug Administration